Vitiligo treatments Narrowband UV-B treatment more effective than psoralen UV-A Therapy
More than vitiligo patients who receive narrowband UV-B vs treatment psoralen and UV-A, have improved over 50% of their body, according to the results of a double-blind randomized trial published in the May issue of Archives of Dermatology.
The combination vitiligo treatments with psoralen followed by UV-A radiation (PUVA) is well established for the treatment of nonsegmental vitiligo, but it has many drawbacks," write Sami Sasi Yones, Guy's, King's and St. Thomas School of Medicine, King's College, London, England, and his colleagues. "In the last decade, there have been reports of good efficiency using narrowband UV-B therapy (NB-UVB, 311-313 nm, TL-01 lamp, Koninklijke Philips Electronics NV, Amsterdam, Netherlands) to deal the disease. To our knowledge, we report the first double-blind randomized trial of PUVA therapy oral psoralen vs NB-UVB therapy for vitiligo.
At a phototherapy unit in a university hospital, 56 patients with nonsegmental vitiligo has suffered twice a week with PUVA therapy or NB-UVB. The main assessment criteria were changing the affected body surface area (BSA) by vitiligo and color match of the repigmented skin against skin unchanged after 48 sessions of therapy, at the end of therapy courses, and 12 months after the end of treatment.
The data were analyzed from 25 patients each in the NB-UVB and PUVA groups who began therapy. The median number of treatments was 47 in the PUVA-treated group and 97 in the NB-UVB-treated group (P = .03), suggesting investigators because of differences in the effectiveness and adverse effects between modalities, which causes patients in the NB-UVB group wanting a longer treatment.
At the end of vitiligo treatments, 16 (64%) of 25 patients in the NB-UVB group showed more than 50% improvement in these BSA, as did 9 (36%) of 25 patients in PUVA group. All patients in the NB-UVB group had an excellent color matching of the repigmented skin, as only 11 (44%) of those in the PUVA (p <.001).
Among patients who completed 48 sessions of vitiligo treatments, improving BSA affected by vitiligo is greater with NB-UVB therapy that therapy with PUVA (P = .007). The superiority of NB-UVB is typically updated 12 months after treatment was stopped. There was no apparent association between successful treatment and duration of vitiligo.
"The mechanism of action of all phototherapy in the treatment of vitiligo May very likely involve the reduction of the immunological procedure followed by stimulation of melanocytes residual, especially those residing in the hair follicles," the authors write. "Our results suggest strongly that in most patients, NB-UVB this form of therapy is preferable to PUVA for the vitiligo treatments.
In an accompanying editorial, Henry W. Lim, MD, and Camile L. Hexsel, MD, Henry Ford Medical Center in Detroit, Michigan, review of published studies and provide an algorithm proposed vitiligo treatments.
"During the last 10 years, several new methods of vitiligo treatments have emerged, including NB-UVB therapy targeted phototherapy, topical immunomodulators, and news calcipotriene," Drs. Hexsel Lim and write. "Refinement of surgical techniques has also continued. ... In 2007, the issue at the management of patients with vitiligo, particularly those relating to sites exposed, is no longer whether to treat or not treat but to decide which method of vitiligo treatments is most appropriate for the individual patient. "
copright 2008 vitiligo treatments vitiligo treatments
NEW TREATMENTS FOR VITILIGO
New treatments for vitiligo
have you heard about a New treatments for vitiligo which is supposed to have a 90 percent success rate called natural co-enzyme tetrahydrobiopterin. Please could you tell me more about this treatment.
Firstly, it is important that you tell your doctor you feel feeble-minded so they can help you cope with your situation. Learn as much as possible about the disease and treatment choices will help you participate in making important decisions about your medical care.
What is vitiligo?
Vitiligo is said to affect one in 200 people. Skin cells produce a pigment called melanin. The vitiligo develops when the skin cells die or are unable to hold the melanin. The skin is stripped of pigment, leaving blotchy marks which are particularly notable on the types of skin darker. It is rare that the pigment back. The underlying cause is uncertain, but the malfunction of the cells could be inherited in some patients, or perhaps linked to poor immune system.
Methods of Treatments for vitiligo
Salaries vary across the world and not all treatments for vitiligo mentioned are regularly available in the UK. The majority of patients have relatively small areas of skin and the standard treatment camouflage with cosmetic creams. Sunscreens are important to prevent sunburn in affected areas, and advice can help patients to accept their condition.
The medical treatments for vitiligo is difficult and often not fully effective. Topical PUVA (Psoralen and ultraviolet A) therapy is to give the patient psoralen, which makes the skin more sensitive to light. It is either applied to the skin or taken by mouth, and the patient is exposed to ultraviolet light. The treatment must be repeated many times in order to obtain partial repigmentation and must be pursued generally six to 18 months.
There are two main potential side effects of PUVA: severe sunburn and blistering and too many black treaties or patches of normal skin surrounding the vitiligo [hyperpigmentation]. They usually disappear when treatment is stopped. Side effects known to include oral psoralen sunburn, nausea and vomiting, itching, abnormal hair growth, and hyperpigmentation. May oral PUVA increases the risk of skin cancer, so patients must apply sunscreen and avoid direct sunlight for 24-48 hours after each treatment and protection UVA wearing sunglasses during a 18 24 hours after each treatment to avoid eye damage, especially cataracts.
Patients in the condition affects more than 50 percent of their body surface area sometimes opt for depigmentation medical application of a drug for normal skin until its color corresponds to the affected areas with vitiligo. The results are permanent and irreversible. Furthermore, the subject of a depigmentation by the individual will always be abnormally sensitive to sunlight.
All surgical therapies for vitiligo, such as skin grafting, should be considered experimental because their effectiveness and side effects remain to be fully defined.
Tétrahydrobioptérine
In 1963, researchers at the National Institute of Mental Health, USA, found that tetrahydrobiopterin, naturally a small molecule, is a coenzyme essential. This means that participates in chemical reactions in the body to increase the rate of reaction. In the last decade, other scientists have developed a treatment that could possibly allow skin pigmentation naturally be changed. They identified tetrahydrobiopterin that the determining factor in depigmentation and developed a cream, pseudocatalase, on the basis of their discovery.
In a pilot study in early 1990, 33 patients with vitiligo have been successfully treated with a topical application of pseudocatalase, calcium, and short-term exposure to UVB light. Repigmentation initial took place in most cases after 2-4 months. Repigmentation complete was achieved with a 90 percent success rate affected faces and hands. In all patients, depigmentation asset was arrested. None of them have developed new lesions during treatments for vitiligo. No recurrence of the disease was observed during a period of two years of monitoring. We are not aware of studies comparing the treatment against others and can not vouch for its safety, efficiency or availability in the United Kingdom.
copyright 2008 - treatments for vitiligo New treatments for vitiligo
have you heard about a New treatments for vitiligo which is supposed to have a 90 percent success rate called natural co-enzyme tetrahydrobiopterin. Please could you tell me more about this treatment.
Firstly, it is important that you tell your doctor you feel feeble-minded so they can help you cope with your situation. Learn as much as possible about the disease and treatment choices will help you participate in making important decisions about your medical care.
What is vitiligo?
Vitiligo is said to affect one in 200 people. Skin cells produce a pigment called melanin. The vitiligo develops when the skin cells die or are unable to hold the melanin. The skin is stripped of pigment, leaving blotchy marks which are particularly notable on the types of skin darker. It is rare that the pigment back. The underlying cause is uncertain, but the malfunction of the cells could be inherited in some patients, or perhaps linked to poor immune system.
Methods of Treatments for vitiligo
Salaries vary across the world and not all treatments for vitiligo mentioned are regularly available in the UK. The majority of patients have relatively small areas of skin and the standard treatment camouflage with cosmetic creams. Sunscreens are important to prevent sunburn in affected areas, and advice can help patients to accept their condition.
The medical treatments for vitiligo is difficult and often not fully effective. Topical PUVA (Psoralen and ultraviolet A) therapy is to give the patient psoralen, which makes the skin more sensitive to light. It is either applied to the skin or taken by mouth, and the patient is exposed to ultraviolet light. The treatment must be repeated many times in order to obtain partial repigmentation and must be pursued generally six to 18 months.
There are two main potential side effects of PUVA: severe sunburn and blistering and too many black treaties or patches of normal skin surrounding the vitiligo [hyperpigmentation]. They usually disappear when treatment is stopped. Side effects known to include oral psoralen sunburn, nausea and vomiting, itching, abnormal hair growth, and hyperpigmentation. May oral PUVA increases the risk of skin cancer, so patients must apply sunscreen and avoid direct sunlight for 24-48 hours after each treatment and protection UVA wearing sunglasses during a 18 24 hours after each treatment to avoid eye damage, especially cataracts.
Patients in the condition affects more than 50 percent of their body surface area sometimes opt for depigmentation medical application of a drug for normal skin until its color corresponds to the affected areas with vitiligo. The results are permanent and irreversible. Furthermore, the subject of a depigmentation by the individual will always be abnormally sensitive to sunlight.
All surgical therapies for vitiligo, such as skin grafting, should be considered experimental because their effectiveness and side effects remain to be fully defined.
Tétrahydrobioptérine
In 1963, researchers at the National Institute of Mental Health, USA, found that tetrahydrobiopterin, naturally a small molecule, is a coenzyme essential. This means that participates in chemical reactions in the body to increase the rate of reaction. In the last decade, other scientists have developed a treatment that could possibly allow skin pigmentation naturally be changed. They identified tetrahydrobiopterin that the determining factor in depigmentation and developed a cream, pseudocatalase, on the basis of their discovery.
In a pilot study in early 1990, 33 patients with vitiligo have been successfully treated with a topical application of pseudocatalase, calcium, and short-term exposure to UVB light. Repigmentation initial took place in most cases after 2-4 months. Repigmentation complete was achieved with a 90 percent success rate affected faces and hands. In all patients, depigmentation asset was arrested. None of them have developed new lesions during treatments for vitiligo. No recurrence of the disease was observed during a period of two years of monitoring. We are not aware of studies comparing the treatment against others and can not vouch for its safety, efficiency or availability in the United Kingdom.
copyright 2008 - treatments for vitiligo New treatments for vitiligo
Subscribe to:
Posts (Atom)
Friday, August 15, 2008
VITILIGO TREATMETNS - NARROWBAND UV-B MORE EFFECTIVE
Vitiligo treatments Narrowband UV-B treatment more effective than psoralen UV-A Therapy
More than vitiligo patients who receive narrowband UV-B vs treatment psoralen and UV-A, have improved over 50% of their body, according to the results of a double-blind randomized trial published in the May issue of Archives of Dermatology.
The combination vitiligo treatments with psoralen followed by UV-A radiation (PUVA) is well established for the treatment of nonsegmental vitiligo, but it has many drawbacks," write Sami Sasi Yones, Guy's, King's and St. Thomas School of Medicine, King's College, London, England, and his colleagues. "In the last decade, there have been reports of good efficiency using narrowband UV-B therapy (NB-UVB, 311-313 nm, TL-01 lamp, Koninklijke Philips Electronics NV, Amsterdam, Netherlands) to deal the disease. To our knowledge, we report the first double-blind randomized trial of PUVA therapy oral psoralen vs NB-UVB therapy for vitiligo.
At a phototherapy unit in a university hospital, 56 patients with nonsegmental vitiligo has suffered twice a week with PUVA therapy or NB-UVB. The main assessment criteria were changing the affected body surface area (BSA) by vitiligo and color match of the repigmented skin against skin unchanged after 48 sessions of therapy, at the end of therapy courses, and 12 months after the end of treatment.
The data were analyzed from 25 patients each in the NB-UVB and PUVA groups who began therapy. The median number of treatments was 47 in the PUVA-treated group and 97 in the NB-UVB-treated group (P = .03), suggesting investigators because of differences in the effectiveness and adverse effects between modalities, which causes patients in the NB-UVB group wanting a longer treatment.
At the end of vitiligo treatments, 16 (64%) of 25 patients in the NB-UVB group showed more than 50% improvement in these BSA, as did 9 (36%) of 25 patients in PUVA group. All patients in the NB-UVB group had an excellent color matching of the repigmented skin, as only 11 (44%) of those in the PUVA (p <.001).
Among patients who completed 48 sessions of vitiligo treatments, improving BSA affected by vitiligo is greater with NB-UVB therapy that therapy with PUVA (P = .007). The superiority of NB-UVB is typically updated 12 months after treatment was stopped. There was no apparent association between successful treatment and duration of vitiligo.
"The mechanism of action of all phototherapy in the treatment of vitiligo May very likely involve the reduction of the immunological procedure followed by stimulation of melanocytes residual, especially those residing in the hair follicles," the authors write. "Our results suggest strongly that in most patients, NB-UVB this form of therapy is preferable to PUVA for the vitiligo treatments.
In an accompanying editorial, Henry W. Lim, MD, and Camile L. Hexsel, MD, Henry Ford Medical Center in Detroit, Michigan, review of published studies and provide an algorithm proposed vitiligo treatments.
"During the last 10 years, several new methods of vitiligo treatments have emerged, including NB-UVB therapy targeted phototherapy, topical immunomodulators, and news calcipotriene," Drs. Hexsel Lim and write. "Refinement of surgical techniques has also continued. ... In 2007, the issue at the management of patients with vitiligo, particularly those relating to sites exposed, is no longer whether to treat or not treat but to decide which method of vitiligo treatments is most appropriate for the individual patient. "
copright 2008 vitiligo treatments vitiligo treatments
More than vitiligo patients who receive narrowband UV-B vs treatment psoralen and UV-A, have improved over 50% of their body, according to the results of a double-blind randomized trial published in the May issue of Archives of Dermatology.
The combination vitiligo treatments with psoralen followed by UV-A radiation (PUVA) is well established for the treatment of nonsegmental vitiligo, but it has many drawbacks," write Sami Sasi Yones, Guy's, King's and St. Thomas School of Medicine, King's College, London, England, and his colleagues. "In the last decade, there have been reports of good efficiency using narrowband UV-B therapy (NB-UVB, 311-313 nm, TL-01 lamp, Koninklijke Philips Electronics NV, Amsterdam, Netherlands) to deal the disease. To our knowledge, we report the first double-blind randomized trial of PUVA therapy oral psoralen vs NB-UVB therapy for vitiligo.
At a phototherapy unit in a university hospital, 56 patients with nonsegmental vitiligo has suffered twice a week with PUVA therapy or NB-UVB. The main assessment criteria were changing the affected body surface area (BSA) by vitiligo and color match of the repigmented skin against skin unchanged after 48 sessions of therapy, at the end of therapy courses, and 12 months after the end of treatment.
The data were analyzed from 25 patients each in the NB-UVB and PUVA groups who began therapy. The median number of treatments was 47 in the PUVA-treated group and 97 in the NB-UVB-treated group (P = .03), suggesting investigators because of differences in the effectiveness and adverse effects between modalities, which causes patients in the NB-UVB group wanting a longer treatment.
At the end of vitiligo treatments, 16 (64%) of 25 patients in the NB-UVB group showed more than 50% improvement in these BSA, as did 9 (36%) of 25 patients in PUVA group. All patients in the NB-UVB group had an excellent color matching of the repigmented skin, as only 11 (44%) of those in the PUVA (p <.001).
Among patients who completed 48 sessions of vitiligo treatments, improving BSA affected by vitiligo is greater with NB-UVB therapy that therapy with PUVA (P = .007). The superiority of NB-UVB is typically updated 12 months after treatment was stopped. There was no apparent association between successful treatment and duration of vitiligo.
"The mechanism of action of all phototherapy in the treatment of vitiligo May very likely involve the reduction of the immunological procedure followed by stimulation of melanocytes residual, especially those residing in the hair follicles," the authors write. "Our results suggest strongly that in most patients, NB-UVB this form of therapy is preferable to PUVA for the vitiligo treatments.
In an accompanying editorial, Henry W. Lim, MD, and Camile L. Hexsel, MD, Henry Ford Medical Center in Detroit, Michigan, review of published studies and provide an algorithm proposed vitiligo treatments.
"During the last 10 years, several new methods of vitiligo treatments have emerged, including NB-UVB therapy targeted phototherapy, topical immunomodulators, and news calcipotriene," Drs. Hexsel Lim and write. "Refinement of surgical techniques has also continued. ... In 2007, the issue at the management of patients with vitiligo, particularly those relating to sites exposed, is no longer whether to treat or not treat but to decide which method of vitiligo treatments is most appropriate for the individual patient. "
copright 2008 vitiligo treatments vitiligo treatments
Sunday, August 10, 2008
NEW TREATMENTS FOR VITILIGO
New treatments for vitiligo
have you heard about a New treatments for vitiligo which is supposed to have a 90 percent success rate called natural co-enzyme tetrahydrobiopterin. Please could you tell me more about this treatment.
Firstly, it is important that you tell your doctor you feel feeble-minded so they can help you cope with your situation. Learn as much as possible about the disease and treatment choices will help you participate in making important decisions about your medical care.
What is vitiligo?
Vitiligo is said to affect one in 200 people. Skin cells produce a pigment called melanin. The vitiligo develops when the skin cells die or are unable to hold the melanin. The skin is stripped of pigment, leaving blotchy marks which are particularly notable on the types of skin darker. It is rare that the pigment back. The underlying cause is uncertain, but the malfunction of the cells could be inherited in some patients, or perhaps linked to poor immune system.
Methods of Treatments for vitiligo
Salaries vary across the world and not all treatments for vitiligo mentioned are regularly available in the UK. The majority of patients have relatively small areas of skin and the standard treatment camouflage with cosmetic creams. Sunscreens are important to prevent sunburn in affected areas, and advice can help patients to accept their condition.
The medical treatments for vitiligo is difficult and often not fully effective. Topical PUVA (Psoralen and ultraviolet A) therapy is to give the patient psoralen, which makes the skin more sensitive to light. It is either applied to the skin or taken by mouth, and the patient is exposed to ultraviolet light. The treatment must be repeated many times in order to obtain partial repigmentation and must be pursued generally six to 18 months.
There are two main potential side effects of PUVA: severe sunburn and blistering and too many black treaties or patches of normal skin surrounding the vitiligo [hyperpigmentation]. They usually disappear when treatment is stopped. Side effects known to include oral psoralen sunburn, nausea and vomiting, itching, abnormal hair growth, and hyperpigmentation. May oral PUVA increases the risk of skin cancer, so patients must apply sunscreen and avoid direct sunlight for 24-48 hours after each treatment and protection UVA wearing sunglasses during a 18 24 hours after each treatment to avoid eye damage, especially cataracts.
Patients in the condition affects more than 50 percent of their body surface area sometimes opt for depigmentation medical application of a drug for normal skin until its color corresponds to the affected areas with vitiligo. The results are permanent and irreversible. Furthermore, the subject of a depigmentation by the individual will always be abnormally sensitive to sunlight.
All surgical therapies for vitiligo, such as skin grafting, should be considered experimental because their effectiveness and side effects remain to be fully defined.
Tétrahydrobioptérine
In 1963, researchers at the National Institute of Mental Health, USA, found that tetrahydrobiopterin, naturally a small molecule, is a coenzyme essential. This means that participates in chemical reactions in the body to increase the rate of reaction. In the last decade, other scientists have developed a treatment that could possibly allow skin pigmentation naturally be changed. They identified tetrahydrobiopterin that the determining factor in depigmentation and developed a cream, pseudocatalase, on the basis of their discovery.
In a pilot study in early 1990, 33 patients with vitiligo have been successfully treated with a topical application of pseudocatalase, calcium, and short-term exposure to UVB light. Repigmentation initial took place in most cases after 2-4 months. Repigmentation complete was achieved with a 90 percent success rate affected faces and hands. In all patients, depigmentation asset was arrested. None of them have developed new lesions during treatments for vitiligo. No recurrence of the disease was observed during a period of two years of monitoring. We are not aware of studies comparing the treatment against others and can not vouch for its safety, efficiency or availability in the United Kingdom.
copyright 2008 - treatments for vitiligo New treatments for vitiligo
have you heard about a New treatments for vitiligo which is supposed to have a 90 percent success rate called natural co-enzyme tetrahydrobiopterin. Please could you tell me more about this treatment.
Firstly, it is important that you tell your doctor you feel feeble-minded so they can help you cope with your situation. Learn as much as possible about the disease and treatment choices will help you participate in making important decisions about your medical care.
What is vitiligo?
Vitiligo is said to affect one in 200 people. Skin cells produce a pigment called melanin. The vitiligo develops when the skin cells die or are unable to hold the melanin. The skin is stripped of pigment, leaving blotchy marks which are particularly notable on the types of skin darker. It is rare that the pigment back. The underlying cause is uncertain, but the malfunction of the cells could be inherited in some patients, or perhaps linked to poor immune system.
Methods of Treatments for vitiligo
Salaries vary across the world and not all treatments for vitiligo mentioned are regularly available in the UK. The majority of patients have relatively small areas of skin and the standard treatment camouflage with cosmetic creams. Sunscreens are important to prevent sunburn in affected areas, and advice can help patients to accept their condition.
The medical treatments for vitiligo is difficult and often not fully effective. Topical PUVA (Psoralen and ultraviolet A) therapy is to give the patient psoralen, which makes the skin more sensitive to light. It is either applied to the skin or taken by mouth, and the patient is exposed to ultraviolet light. The treatment must be repeated many times in order to obtain partial repigmentation and must be pursued generally six to 18 months.
There are two main potential side effects of PUVA: severe sunburn and blistering and too many black treaties or patches of normal skin surrounding the vitiligo [hyperpigmentation]. They usually disappear when treatment is stopped. Side effects known to include oral psoralen sunburn, nausea and vomiting, itching, abnormal hair growth, and hyperpigmentation. May oral PUVA increases the risk of skin cancer, so patients must apply sunscreen and avoid direct sunlight for 24-48 hours after each treatment and protection UVA wearing sunglasses during a 18 24 hours after each treatment to avoid eye damage, especially cataracts.
Patients in the condition affects more than 50 percent of their body surface area sometimes opt for depigmentation medical application of a drug for normal skin until its color corresponds to the affected areas with vitiligo. The results are permanent and irreversible. Furthermore, the subject of a depigmentation by the individual will always be abnormally sensitive to sunlight.
All surgical therapies for vitiligo, such as skin grafting, should be considered experimental because their effectiveness and side effects remain to be fully defined.
Tétrahydrobioptérine
In 1963, researchers at the National Institute of Mental Health, USA, found that tetrahydrobiopterin, naturally a small molecule, is a coenzyme essential. This means that participates in chemical reactions in the body to increase the rate of reaction. In the last decade, other scientists have developed a treatment that could possibly allow skin pigmentation naturally be changed. They identified tetrahydrobiopterin that the determining factor in depigmentation and developed a cream, pseudocatalase, on the basis of their discovery.
In a pilot study in early 1990, 33 patients with vitiligo have been successfully treated with a topical application of pseudocatalase, calcium, and short-term exposure to UVB light. Repigmentation initial took place in most cases after 2-4 months. Repigmentation complete was achieved with a 90 percent success rate affected faces and hands. In all patients, depigmentation asset was arrested. None of them have developed new lesions during treatments for vitiligo. No recurrence of the disease was observed during a period of two years of monitoring. We are not aware of studies comparing the treatment against others and can not vouch for its safety, efficiency or availability in the United Kingdom.
copyright 2008 - treatments for vitiligo New treatments for vitiligo
Subscribe to:
Posts (Atom)